US Stock Market Move | Latigo Biotherapeutics (LTGO.US) debuts on the U.S. stock market, with its stock price rising over 14% after opening.
As of the time of this report, the stock has risen over 14%, trading at $20.53.
On Friday, non-opioid painkiller developer Latigo Biotherapeutics (LTGO.US) debuted on the US stock market. As of this writing, the stock is up over 14%, trading at $20.53. Latigo is committed to developing non-opioid analgesics targeting the Nav1.8 sodium ion channel. Its core candidate, LTG-001, is an oral Nav1.8 inhibitor primarily used for treating moderate to severe acute pain, including postoperative pain. This drug aims to provide analgesic effects comparable to those of opioids while avoiding the risk of addiction. Nav1.8 is primarily expressed in peripheral pain-sensing neurons, and its inhibitors do not act on the central nervous system, thus lacking addictive properties.
Related Articles
Data center operator Switch has secretly filed for an IPO on the US stock market, with the earliest listing expected in November.
HK Bull/Bear Outstanding Qty Ratio(49:51) | August 8
Overnight US stocks | In July, non-farm payrolls unexpectedly declined, and the S&P 500 index reached a record closing high. SpaceX (SPCX.US) surged nearly 16%.
Data center operator Switch has secretly filed for an IPO on the US stock market, with the earliest listing expected in November.
HK Bull/Bear Outstanding Qty Ratio(49:51) | August 8
Overnight US stocks | In July, non-farm payrolls unexpectedly declined, and the S&P 500 index reached a record closing high. SpaceX (SPCX.US) surged nearly 16%.
RECOMMEND
